Provention Bio Announces Positive Interim Results from First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

Provention Bio, Inc. announced positive interim results from PROVENT, a first-in-human study of PRV-101, a polyvalent inactivated coxsackievirus B vaccine candidate targeting all five key CVB strains associated with type 1 diabetes autoimmunity.